20Feb 2017
MPubmed

Deletion of connexin (Cx) 37 in mice leads to increased cancellous bone mass due to defective osteoclast differentiation. Paradoxically; however, Cx37-deficient mice exhibit reduced cortical thickness accompanied by higher bone strength,suggesting a contribution of Cx37 to bone matrix composition. Thus, we investigated whether global deletion of Cx37 alters the composition of phentermine organic bone extracellular matrix.m echanistic studies showed Wnt/β-catenin activation in MLO-Y4 osteocytic cells, L5 vertebra, and authentic calvaria-derived osteocytes isolated by fluorescent-activated cell sorter. Our findings demonstrate that altered profile of the bone matrix components in Cx37-deficient mice acts in favor of higher resistance to Fracture in long bones.

Pacheco-Costa R, Kadakia JR, Atkinson EG, Wallace JM, Plotkin LI, Reginato RD

30Ene 2017

Results: romosozumab significantly increased integral vBMD and BMC at the lumbar spine and total hip from baseline, and compared with placebo and teriparatide (all p < 0.05). Trabecular vertebral vBMD improved significantly and similarly from baseline (p < 0.05) with both romosozumab (18.3%) and teriparatide (20.1%), whereas cortical vertebral vBMD gains were larger with romosozumab compared with teriparatide (13.7% versus 5.7%, p < 0.0001). Trabecular hip vBMD gains were significantly larger with romosozumab than with teriparatide (10.8% versus 4.2%, p = 0.01), but were similar for cortical vBMD (1.1% versus -0.9%, p = 0.12). Cortical BMC gains were larger with romosozumab compared with teriparatide at both the spine (23.3% versus 10.9%, p < 0.0001) and hip (3.4% versus 0.0%, p = 0.03).

Más Información

Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C, Goemaere S, Fuerst T, Yang YC, Grauer A, Libanati C.

30Ene 2017
MPubmed

Among patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, the use of zoledronic acid every 12 weeks compared with the standard dosing interval of every 4 weeks did not result in an increased risk of skeletal events over 2 years. This longer interval may be an acceptable treatment option.

Más Información

Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O’Connor T, Velasco MR Jr, Weckstein D, O’Mara A, Loprinzi CL, Shapiro CL

30Ene 2017
MPubmed

This review presents the current state of the art in the diagnosis and management of PHPT and updates the Canadian Position paper on PHPT. An overview of the impact of PHPT on the skeleton and other target organs is presented with international consensus. Differences in the international presentation of this condition are also summarized.

Más Información

Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, Thakker R, D’Amour P, Paul T, Van Uum S, Shrayyef MZ, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT Jr, Brandi ML, Bilezikian JP.

30Ene 2017
MPubmed

Fragility fractures of the hip have a major impact on the lives of patients and their families. This study highlights significant geographical variation in secondary fracture prevention with even the highest performing regions failing the majority of patients despite robust evidence supporting the benefits of diagnosis and treatment. CONCLUSIONS: Significant geographic differences exist in prescribing of anti-osteoporosis drugs after hip fracture despite adjustment for potential confounders. Further work examining differences in health care provision may inform strategies to improve secondary fracture prevention after hip fracture.Watch Full Movie Online Streaming Online and Download

Más Información

Shah A, Prieto-Alhambra D, Hawley S, Delmestri A, Lippett j,Cooper C, Judge A, Javaid MK; REFReSH study team.

20Ene 2017
MPubmed

J Am Soc Nephrol. 2016 Dec 7

Parathyroid hormone (PTH) is a primary calcium regulatory hormone. Elevated serum PTH concentrations in primary and secondary hyperparathyroidism have been associated with bone disease, hypertension, and in some studies, cardiovascular mortality. Genetic causes of variation in circulating PTH concentrations are incompletely understood. This study performed a genome-wide association study of serum PTH concentrations among 29,155 participants of European ancestry from 13 cohort  studies.

 

Autor: RobinsonCC,LutseyPL,KleberME,NielsonCM,MitchellBDBisJC,EnyKMPortasL,ErikssonJ,LorentznM,KollerDLMilaneschiY,TeumerA,PilzS,NethanderM,SelvinE,TanGW,WengLC,WongHS,LaiD,PeacockM,HannemannA,VölkerU,HomuthG,NaukM,MurgiaF,PatteeJW,OrwollE,ZmudaJM,RianchoJA

20Ene 2017
MPubmed

J Bone Miner Res. 2016 Dec 7. doi: 10.1002/jbmr.3051.Watch movie online The Transporter Refueled (2015)

The majority of osteoporosis medications are antiresorptive agents, which reduce the rate of bone remodeling. Within this group are the bisphosphonates, which inhibit protein prenylation in the mature osteoclast, reducing osteoclast capacity to resorb bone(1) and denosumab, a monoclonal antibody to rank ligand that inhibits osteoclast formation, function and survival. Although several new anabolic agents are in development(3-5) , teriparatide is currently the only  available anabolic therapy for osteoporosis in the United States, with the addition of only PTH(1-84) in the EU [referred to as PTH).

 

Autor: Cosman F, Nieves JW, Dempster D

20Ene 2017
MPubmed

Calcif Tissue Int. 2016 Dec 7Watch Full Movie Online Streaming Online and Download

The adipokine adiponectin affects multiple target tissues and plays important roles in glucose metabolism and whole-body energy homeostasis. Circulating adiponectin levels in obese people are lower than in non-obese, and increased serum adiponectin is associated with weight loss. Results of these studies are not entirely congruent, partly due to variation among experimental systems and partly due to the complex nature of adiponectin signaling, which involves a combination of multiple direct and indirect mechanisms.

 

Autor: Naot D, Musson DS, Cornish J

20Ene 2017
MPubmed

Curr Osteoporos Rep. 2016 Dec;14(6):320-326.

Diabetic patients have a higher fracture risk than expected by their bone mineral density (BMD). Poor bone quality is the most suitable and explainable cause for the elevated fracture risk in this population. Advanced glycation end products (AGEs), physically affect the properties of the bone material, one of a component of bone quality, through their accumulation in the bone collagen fibers.

 

Autor: Yamamoto M, Sugimoto T

13Dic 2016
MPubmed

J Bone Joint Surg Am. 2016 Nov 16;98(22):1868-1878.

Osteoporosis drugs might affect fracture-healing. We therefore studied the effects of teriparatide in comparison with risedronate on recovery after pertrochanteric hip fractures. Teriparatide was associated with less pain and a shorter time to complete the TUG test between 6 and 26 weeks compared with risedronate. Other fracture-recovery outcomes were similar. The results should be interpreted with caution as these were secondary end points.

Autor: Aspenberg P, Malouf J, Tarantino U, García-Hernández P, Corradini C, Overgaard S, Stepan JJ, Borris , Lespessailles E,Frihagen F, Papavasiliou K, Petto H, Caeiro JR, Marin F